Showing 7041-7050 of 8238 results for "".
- New HelloBello Baby Care Products Make a Big Splash at Walmarthttps://practicaldermatology.com/news/new-hellobello-baby-care-products-make-a-big-splash-at-walmart/2459983/Walmart is rolling out a host of new products from HelloBello, an affordable plant-based baby care line co-founded by Kristen Bell and Dax Shepard. Hello Bello will launch with 10 products including diapers, wipes, shampoo & body wash, bubb
- Pulse Biosciences, Inc's CellFX System Performs Well in Sebaceous Hyperplasia Studyhttps://practicaldermatology.com/news/pulse-biosciences-incs-cellfx-system-performs-well-in-sebaceous-hyperplasia-study/2459987/Pulse Biosciences, Inc’s CellFX Nano-Pulse Stimulation system cleared more than 90 percent of sebaceous hyperplasia (SH) lesions in a study presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Candela Unveils New Corporate Identity at the 2019 AAD Annual Meetinghttps://practicaldermatology.com/news/candela-unveils-new-corporate-identity-at-the-2019-aad-annual-meeting/2459874/Syneron-Candela has rebranded the company to Candela and unveiled its new corporate branding at the American Academy of Dermatology (AAD) Annual Meeting. The new corporate identity reflects the unification of the Syneron and Candela brands and is designed to support continued global market growth
- Arkansas Gets SUNucatedhttps://practicaldermatology.com/news/arkansas-gets-sunucated/2459875/Arkansas has joined 18 other states in adopting legislation to allow children to possess and apply sunscreen at school. Governor Asa Hutchinson signed into law HB 1167, which was co-sponsored by Representative Lee Johnson, MD, and carried through the Senate by Senator David Wallace.
- Regenerative Medicine Breakthrough: Mobile Bedside Bioprinter May Heal Woundshttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-mobile-bedside-bioprinter-may-heal-wounds/2459876/Researchers have created a mobile skin bioprinting system that allows bi-layered skin to be printed directly into a wound. The team demonstrated proof-of-concept of the system by printing skin directly onto pre-clinical models, and the next step is to conduct a clinical trial in humans, t
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- FDA Clears Sculptura Radiation Oncology System from Sensus Healthcarehttps://practicaldermatology.com/news/fda-clears-sculptura-radiation-oncology-system-from-sensus-healthcare/2459884/The FDA has granted market clearance for the Sculptura radiation oncology system from Sensus Healthcare, Inc. With a single treatment during surgery, Sculptura can provide cancer patients and physicians a single radiation treatment at the
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&